Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792841 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
NCT03792841: Clinical Trial Phase 1 study, sponsored by Amgen.
NCT03792841 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 212 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03792841, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
Study Summary
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Primary Outcome
Parts 1, 2, 3, 4, 5, and 6 of the study
Interventions
- DRUG Pembrolizumab
- DRUG Etanercept
- DRUG acapatamab
- DRUG Cytochrome P450 (CYP) Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 1 |
Why NCT03792841 stopped before completion
NCT03792841 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03792841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03792841 about?
NCT03792841 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC". A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or rec...
What is the current status of trial NCT03792841?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2019-02-05. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT03792841?
The interventions under investigation include: Pembrolizumab (DRUG), Etanercept (DRUG), acapatamab (DRUG), Cytochrome P450 (CYP) Cocktail (DRUG).
Who is sponsoring clinical trial NCT03792841?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03792841's enrollment target sits among peer trials
212 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI